Protalix BioTherapeutics, Inc. (PLX) Stock Analysis

Protalix BioTherapeutics is a commercial-stage rare-disease biotechnology company whose ProCellEx platform produces recombinant therapeutic proteins in plant cells rather than mammalian cultures. Its approved products are Elelyso for Gaucher disease, commercialized with Pfizer, and Elfabrio for adult Fabry disease, commercialized with Chiesi. The platform offers lower manufacturing complexity, reduced viral-contamination risk, and potentially superior economics; Elelyso was initially priced 25% below Cerezyme. **Commercial momentum accelerated in 2026:** first-half revenue reached $53.646 million versus $25.771 million a year earlier, including a $25.0 million Chiesi milestone, while net income was $22.094 million. Full-year revenue guidance is $78.0–$83.0 million, with a midpoint of $80.5 million, versus $52.7 million in 2025. **The investment case is asymmetric but execution-sensitive:** Elfabrio’s every-four-weeks EU dosing could support market share gains, while PRX-115 Phase 2 data are expected in H2 2027. At approximately $2.46, PLX trades at 12.58x TTM P/E and 2.43x–2.6x P/S, below biotech peers; the report cites analyst targets of $11.00–$11.22. The key offset is dependence on a single Carmiel, Israel manufacturing site and two major partners.